C60 (Buckminsterfullerene)

C60 (Buckminsterfullerene) presents a high safety risk that outweighs its modest antioxidant claims, so most users should proceed only if they accept uncertain long-term toxicity. The primary concern stems from light-induced degradation of oil-solubilized C60, which animal studies have linked to organ damage and reduced lifespan Shytikov 2021. In addition, the European SCCS opinion notes that genotoxic potential of fullerene molecules cannot be excluded, leaving a regulatory gap for oral use SCCS 2023. Human pharmacokinetic data are absent, and no Phase I safety trial has been published, meaning tissue accumulation and reproductive effects remain speculative. Together these uncertainties push the downside score toward the upper range and suggest that cautious individuals, pregnant people, and those with existing health conditions should avoid routine supplementation.

Safety risk (4.3/5.0). C60 safety risk is high because the worst-case safety risk remains unresolved, not because common severe harm is documented in humans. The central concerns are light-degraded C60-oil animal toxicity, SCCS 2023 inability to exclude fullerene genotoxicity, reproductive-toxicology signals from fullerene exposure models, long tissue retention, and no human Phase I oral pharmacokinetic or chronic-safety trial. The FDA warning-letter context also matters because disease claims have outrun evidence. The score stays at 4.3 because multiple independent uncertainty clusters remain active.

Side effect profile (2.5/5.0). C60 reported side effects are mostly mild-to-moderate in consumer communities, but rates are not measured. Users report photosensitivity or easier sunburn, gastrointestinal distress with dose escalation, kidney-area discomfort, staining, and sleep or mood changes in either direction. Photosensitizing-drug interactions are untested but concerning because C60 chemistry is light-reactive. The side-effect score stays separate from the worst-case safety risk: community tolerability often looks acceptable, yet the absence of systematic human surveillance prevents a low score. Dose reduction, opaque storage, refrigeration, and discontinuation are practical risk controls.

Financial cost (3.0/5.0). C60 cost is meaningful for a weak-evidence supplement. Therapeutic-grade vacuum-baked or sublimated C60 oil often costs $60-100/month at common anecdotal dosing. Cheap industrial-grade products may cost $20-30/month, but residual-solvent, concentration, and degradation concerns make them poor choices for a motivated safety-conscious user. The opportunity is especially stark because the same budget can fund better-supported interventions such as astaxanthin, urolithin A, or magnesium. C60 is not financially ruinous, but the evidence-per-dollar ratio is weak.

Time / effort burden (1.8/5.0). C60 is operationally easy but storage-sensitive. The dosing act takes under two minutes: measure oil, take it with food, and put it away. The friction comes from the required handling discipline. C60 oil should remain refrigerated, opaque, protected from light, and sourced with credible purity documentation. Travel, careless countertop storage, or clear bottles undermine the protocol. That keeps effort above a normal capsule supplement while still below practices that require 10-20 minutes daily. The main effort is not time. It is avoiding product and storage failure.

Opportunity cost (3.0/5.0). C60 opportunity cost is real because it consumes supplement budget and attention that could go to better-validated longevity and antioxidant tools. For oxidative stress, mitochondrial support, and recovery, the user has cleaner options with human endpoint data. C60 can technically stack with other interventions, so the opportunity score is not extreme. But for most people, choosing C60 before evidence-backed basics is poor sequencing. Exercise, sleep, protein, creatine, omega-3, urolithin A, astaxanthin, and magnesium should come first. C60 belongs near the experimental end of a mature stack, if anywhere.

Dependency / withdrawal (1.5/5.0). C60 has no known dependency, withdrawal, tolerance escalation, addictive pharmacology, or rebound syndrome. Slow tissue washout is not the same as dependency. There is also no evidence that C60 downregulates endogenous antioxidant systems in humans or creates a biological need to continue. Community reports do not describe withdrawal; they describe either no effect or fading subjective benefits after stopping. The score stays near floor because the dependency pathway is not the problem. The problem is unresolved safety and weak efficacy, not compulsive use or discontinuation difficulty.

Reversibility (2.5/5.0). C60 reversibility is mixed because exposure may be slow to clear. There are no permanent biological changes documented from typical consumer dosing, and subjective effects appear reversible. But rodent biodistribution suggests C60 can persist in tissues such as liver, spleen, and adrenals, and no human washout pharmacokinetic study exists. That means a user cannot confidently stop today and know exposure is gone tomorrow. Reversibility stays mid-range: likely functionally reversible, but not quickly reversible if a delayed safety concern or product-quality problem emerges.